VES structure
|
Common Name | VES | ||
|---|---|---|---|---|
| CAS Number | 4345-03-3 | Molecular Weight | 530.779 | |
| Density | 1.0±0.1 g/cm3 | Boiling Point | 625.8±55.0 °C at 760 mmHg | |
| Molecular Formula | C33H54O5 | Melting Point | ~76 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 187.0±25.0 °C | |
Use of VESD-α-Tocopherol Succinate (Vitamin E succinate) is an antioxidant tocopherol and a salt form of vitamin E. D-α-Tocopherol Succinate inhibits Cisplatin (HY-17394)-induced cytotoxicity. D-α-Tocopherol Succinate can be used for the research of cancer[1][2]. |
| Name | α-Tocopheryl Succinate |
|---|---|
| Synonym | More Synonyms |
| Description | D-α-Tocopherol Succinate (Vitamin E succinate) is an antioxidant tocopherol and a salt form of vitamin E. D-α-Tocopherol Succinate inhibits Cisplatin (HY-17394)-induced cytotoxicity. D-α-Tocopherol Succinate can be used for the research of cancer[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | D-α-Tocopherol Succinate (1-20 μM; 24 hours) shows cytotoxicity to HEI-OC1 cells[1]. D-α-Tocopherol Succinate (10 μM; 48 hours) protects HEI-OC1 cells against cisplatin-induced ototoxicity and inhibits caspase-3 activity[1]. D-α-Tocopherol Succinate (0-50 μM; 18 hours) shows cytotoxicity to TC-1 tumor cells[2]. Cell Cytotoxicity Assay[1] Cell Line: HEI-OC1 cell line Concentration: 1-20 μM Incubation Time: 24 hours Result: Significantly induced cytotoxicity at a concentration of 20 μM and showed a higher cytotoxicity potency compared with 10 μM. Cell Viability Assay[1] Cell Line: HEI-OC1 cell line Concentration: 10 μM Incubation Time: 48 hours Result: Increased cisplatin-induced cell population. Inhibited cisplatin-induced necrotic, ROS production and late apoptosis. Decreased cleaved PARP and inhibited the expression of caspase-3 which related to cisplatin-induced apoptosis. Cell Cytotoxicity Assay[2] Cell Line: TC-1 tumor cells Concentration: 0, 25 and 50 μM Incubation Time: 18 hours Result: Dose-dependently showed cytotoxic and induced a higher percentage of necrotic TC-1 cells as opposed to apoptotic cells. |
| In Vivo | D-α-Tocopherol Succinate (1-2 mg/kg; i.p. three times at 2 day intervals from TC-1 tumor cells injection for 10 days to 14 days) shows antitumor effects to mice with TC-1 tumor[2]. Animal Model: Six- to eight-week-old female C57BL/6 mice with TC-1 tumor cells[2] Dosage: 1 and 2 mg/kg Administration: Intraperitoneal injection; 1 and 2 mg/kg three times at 2 day intervals; from TC-1 tumor cells injection for 10 days to 14 days Result: Dreased the tumor volume, especially with a dose of 2 mg/kg. |
| References |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 625.8±55.0 °C at 760 mmHg |
| Melting Point | ~76 °C(lit.) |
| Molecular Formula | C33H54O5 |
| Molecular Weight | 530.779 |
| Flash Point | 187.0±25.0 °C |
| Exact Mass | 530.397095 |
| PSA | 72.83000 |
| LogP | 11.88 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.498 |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 1 |
| RTECS | EJ9984000 |
|
~84%
VES CAS#:4345-03-3 |
| Literature: Redoules, Daniel; Bordat, Pascal; Perie, Jean-Jacques Patent: US2004/236098 A1, 2004 ; Location in patent: Page 4 ; |
|
~72%
VES CAS#:4345-03-3 |
| Literature: Redoules, Daniel; Bordat, Pascal; Perie, Jean-Jacques Patent: US2004/236098 A1, 2004 ; Location in patent: Page 4 ; |
|
~%
VES CAS#:4345-03-3 |
| Literature: US2486539 , ; |
|
~%
VES CAS#:4345-03-3 |
| Literature: US2486539 , ; |
|
Influence of process and formulation parameters on dissolution and stability characteristics of Kollidon® VA 64 hot-melt extrudates.
AAPS PharmSciTech 16(2) , 444-54, (2015) The objective of the present study was to investigate the effects of processing variables and formulation factors on the characteristics of hot-melt extrudates containing a copolymer (Kollidon® VA 64)... |
|
|
Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer.
Biomaterials 64 , 10-20, (2015) Metastasis is one of the major obstacles for the successful therapy of breast cancer. To inhibit the metastasis and growth of breast cancer simultaneously, a new docetaxel (DTX) loaded shrapnel nano d... |
|
|
p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.
Mol. Carcinog. 54 , 618-31, (2015) p66Shc functions as a longevity protein in murine and exhibits oxidase activity in regulating diverse biological activities. In this study, we investigated the role of p66Shc protein in regulating ova... |
| a-Tocopheryl Succinate |
| Butanedioic Acid (2R-(2R*(4R*,8R*)))-mono(3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) Ester |
| a-Tocopheryl Acid Succinate |
| α-Tocopheryl acid succinate |
| (+)-α-Tocopheryl succinate |
| VES |
| EINECS 224-403-8 |
| D-α-Tocopherol succinate |
| (+)-2,5,7,8-Tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanyl Hydrogen Succinate |
| a-Tocopherol Acid Succinate |
| mono((2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) butanedioate |
| Butanedioic acid Mono((2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) Ester |
| d-alpha-Tocopherol succinate(E) |
| a-Tocopheryl Hydrogen Succinate |
| Butanedioic acid, mono[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl] ester |
| 4-Oxo-4-({(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-yl}oxy)butanoic acid |
| a-Tocopherol Hemisuccinate |
| Vitamin E Succinate |
| MFCD00072055 |
| Covitol 1210 |
| (+)-a-Tocopheryl Succinate |